Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications

Gynecologic Oncology

Volumn 116, Issue 3, 2010, Pages 345-350

  Lesnock, Jamie L ^a   Richard, Scott D ^a   Zorn, Kristin K ^a   Krivak, Thomas C ^a   Beriwal, Sushil ^a   Sukumvanich, Paniti ^a   McBee Jr , William C ^a   Kelley, Joseph L ^a   Edwards, Robert P ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Advanced ovarian cancer; IP catheter; IP chemotherapy

Indexed keywords

CISPLATIN; CREATININE; PACLITAXEL;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURGERY; CATHETER COMPLICATION; CATHETER INFECTION; CATHETER OCCLUSION; CYTOREDUCTIVE SURGERY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; HUMAN; LAPAROSCOPY; LAPAROTOMY; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; SYNCOPE; UTERINE TUBE CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CATHETERS, INDWELLING; CISPLATIN; FEMALE; HUMANS; INFUSIONS, PARENTERAL; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; TAXOIDS;

EID: 75749134463     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.11.009     Document Type: Article

References (26)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., and Thun M.J. Cancer statistics, 2009. CA Cancer J. Clin. 59 (2009) 225-249
2. http://www.cancer.gov
3. Alberts D.S., Liu P.Y., Hannigan E.V., O'Toole R., Williams S.D., Young J.A., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 35 26 (1996) 1950-1955
4. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19 4 (2001) 1001-1007
5. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 1 (2006) 34-43
6. www.nlm.nih.gov/databases/alerts/ovarian_ip_chemo.html
7. Naumann R.W., Sukumvanich P., and Edwards R.P. Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer. Gynecol. Oncol. 114 1 (2009) 37-41
8. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected Stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 17 (2003) 3194-3200
9. Walker J.L., Armstrong D.K., Huang H.Q., Fowler J., Webster K., Burger R.A., et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol. Oncol. 100 (2006) 27-32
10. Alberts D.S., Green S., Hannigan E.V., et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J. Clin. Oncol. 10 (1992) 706-717
11. Swenerton K., Jeffrey J., and Stuart G. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials group. J. Clin. Oncol. 10 (1992) 718-726
12. McGuire W.P., Hoskins W.J., Brady M.F., et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 13 (1995) 1589-1599
13. Dittrich C.h., Sevelda P., Salazer H., et al. Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients: 10-year results of a prospective randomized phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin. Eur. J. Cancer 39 (2003) 1129-1140
14. Connelly E., Markman M., Kennedy A., et al. Paclitaxel delivered as a 3-hour infusion with cisplatin in patients with gynecologic cancer: unexpected incidence of neurotoxicity. Gynecol. Oncol. 62 (1996) 166-168
15. Markman M., and Walker J.L. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J. Clin. Oncol. 24 6 (2006) 988-994
16. Yen M., Twu N., Chiung-Ru L., Huann-Cheng H., Kuan-Chong C., and Chi-Mou J. Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer. Gynecol. Oncol. 114 (2009) 415-419
17. Tewari D., Chunqiao T., Armstrong D.K., Markman M., Herzog T.J., and Monk B.J. The clinical-pathological factors relevant to intraperitoneal chemotherapy in ovarian cancer: an analysis of two Gynecologic Oncology Group trials. 2008 ASCO Annual Meeting. J. Clin. Oncol. 26 (2008) abstr 5549
18. Pfeifle C.E., Howell S.B., Markman M., and Lucas W.E. Totally implantable system for peritoneal access. J. Clin. Oncol. 2 11 (1984) 1277-1280
19. Piccart M.J., Speyer J.L., Markman M., ten Bokkel Huinink W.W., Alberts D., Jenkins J., and Muggia F. Intraperitoneal chemotherapy: technical experience at five institutions. Semin. Oncol. 12 3 Suppl 4 (1985) 90-96
20. Davidson S.A., Rubin S.C., Markman M., Jones W.B., Hakes T.B., Reichman B., et al. Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system. Gynecol. Oncol. 41 2 (1991) 101-106
21. Braly P., Doroshow J., and Hoff S. Technical aspects of intraperitoneal chemotherapy in abdominal carcinomatosis. Gynecol. Oncol. 25 3 (1986) 319-333
22. Sakuragi N., Nakajima A., Nomura E., Noro N., Yamada H., Yamamoto R., et al. Complications relating to intraperitoneal administration of cisplatin or carboplatin for ovarian carcinoma. Gynecol. Oncol. 79 3 (2000) 420-423
23. Makhija S., Leitao M., Sabbatini P., Bellin N., Almadrones L., Leon L., et al. Complications associated with intraperitoneal chemotherapy catheters. Gynecol. Oncol. 81 1 (2001) 77-81
24. Fujiwara K., Sakuragi N., Suzuki S., Yoshida N., Maehata K., Nishiya M., et al. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecol. Oncol. 90 3 (2003) 637-643
25. Landrum L.M., Gold M.A., Moore K.N., Myers T.K.N., McMeekin D.S., and Walker J.L. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates. Gynecol. Oncol. 108 (2007) 247-342
26. Black D., Levine D.A., Nicoll L., Chou J.F., Iasonos A., Brown C.L., et al. Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer. Gynecol. Oncol. 109 (2008) 39-41